Related Experiment Video
Updated: Jun 7, 2026
Reconstruct Human Retinoblastoma In Vitro
Published on: October 11, 2022
Differentiation potential of human retinoblastoma cells
1Center for Hearing and Deafness, University at Buffalo, 3435 Main Street, Buffalo, NY 14214, USA. gseigel@frontiernet.net
Abstract:
Retinoblastoma (RB), an intraocular tumor of childhood, contains small subpopulation(s) of stem-like cells expressing the ABCG2 drug transporter that can efflux standard chemotherapies. Since chemo-resistant stem-like cells appear to be a driving force in tumor progression and metastasis for a variety of cancers, innovative treatment strategies are necessary to eradicate these rare cell populations. Terminal differentiation, as a means to deplete the pool of stem-like cells in RB, is an intriguing approach to cancer therapeutics. However, the full extent of RB differentiation remains unknown. Differentiation of RB cells has been examined in response to a variety of different agents, including retinoic acid/sodium butyrate, Pigment Epithelial-Derived Factor, as well as Succinylated Concanavalin A. RB cells exhibit morphologic and phenotypic responses to these differentiating agents, although the permanence of these effects is questionable due to reversibility. Further study of differentiation programs may lead to new approaches in the design of strategies to combat the initiation and progression of RB in vivo.
Insights
Retinoblastoma stem-like cells resist chemotherapy. Inducing differentiation offers a potential strategy to eliminate these cells and combat tumor progression.
Area of Science:
- Oncology
- Stem Cell Biology
- Pharmacology
Background:
- Retinoblastoma (RB) features stem-like cells expressing ABCG2, conferring chemoresistance.
- These chemo-resistant cells drive tumor progression and metastasis in various cancers.
- Targeting these rare cell populations is crucial for effective cancer therapeutics.
Purpose of the Study:
- To investigate the potential of terminal differentiation as a therapeutic strategy for retinoblastoma.
- To explore the extent and permanence of retinoblastoma cell differentiation.
Main Methods:
- Examining retinoblastoma cell differentiation in response to agents like retinoic acid/sodium butyrate, Pigment Epithelial-Derived Factor, and Succinylated Concanavalin A.
- Assessing morphologic and phenotypic changes in RB cells upon treatment.
Main Results:
- Retinoblastoma cells demonstrated morphologic and phenotypic responses to various differentiating agents.
- The long-term stability of these differentiation effects remains uncertain due to observed reversibility.
Conclusions:
- Terminal differentiation is a promising, yet incompletely understood, approach for retinoblastoma therapy.
- Further research into RB differentiation programs is needed to develop novel in vivo treatment strategies.
- Understanding differentiation may lead to new methods to combat retinoblastoma initiation and progression.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...